Tweet
Proactive Investors Australia
<img alt="" height="1" width="1" />
Prana Biotech Plunges 76% as Drug Fails in Alzheimer's Study
Businessweek
Prana Biotechnology Ltd. (PBT) plunged as much as 76 percent in trading before U.S. exchanges opened after the company's experimental drug for Alzheimer's disease failed to help patients in a clinical trial. The treatment, PBT2, didn't show a statistically ...
Prana Biotech's Alzheimer's Treatment Doesn't Meet EndpointsWall Street Journal
Prana says drug fails Alzheimer's disease studyReuters
Prana Announces Results Of Phase 2 Imagine Trial Of PBT2 In Alzheimer's ...RTT News
StreetInsider.com (subscription) -Proactive Investors Australia
all 8 news articles »
More...